Identification and solution of drug-related problems in the neurology unit of a tertiary hospital in China

Pengpeng Liu¹, Guangyao Li¹, Mei Han² and Chao Zhang¹*

Abstract

Background: The prevalence and characteristics of drug-related problems (DRPs) and factors associated with the occurrence of DRPs in the neurology unit in China remain unknown. This study aimed to determine the prevalence, characteristics and severity ratings of DRPs and identify factors associated with the occurrence of DRPs in the neurology unit of a tertiary care and academic teaching hospital in China.

Methods: A retrospective study of DRPs and pharmacists’ interventions for neurology patients was performed during a non-consecutive 24-month study period. Patient demographics and clinical characteristics, and pharmacist’s intervention records were collected. The characteristics and severity ratings of DRPs were categorized using the Pharmaceutical Care Network Europe (PCNE) DRP classification tool V9.00 and the National Coordinating Council for Medication Error Reporting and Prevention (NCC-MERP) classification respectively.

Results: A total of 242 DRPs were detected for 974 admitted patients, an average of 0.25 DRPs per patient. Treatment safety was the major type of DRPs (106; 43.8%) followed by treatment effectiveness (78; 32.2%). The primary causes of DRPs were drug selection (124; 44.1%) and dose selection (92; 32.7%). Clinical pharmacists provided 525 interventions, and most interventions occurred at the prescriber level (241; 45.9%). A total of 91.4% of these interventions were accepted, contributing to solving 93.0% of the identified problems. The majority of DRPs (210; 86.8%) were rated at severity categories B to D (causing no patient harm). Multiple logistic regression showed that creatinine clearance, number of medications used, nasogastric feeding, diabetes, and infectious diseases were associated with more frequent DRPs (p < 0.05).

Conclusions: DRPs are relatively common in the neurology unit in China, with primary causes of drug and dose selection, and clinical pharmacists can effectively reduce and prevent DRPs to optimize medication therapy.

Keywords: Drug-related problems, Neurology unit, PCNE, Pharmacists’ intervention
2005 [6]. DRPs occur for many reasons, for example, inappropriate combination of medications, inappropriate medication form, and medication dose too high, leading to an increase in morbidity, mortality, and medical costs [4–6].

The prevention, identification and solution of DRPs constitutes the core of pharmaceutical care in which clinical pharmacists, together with the multi-disciplinary team (MDT), make an effort to improve therapeutic outcomes and the quality of life in patients [7–9]. Clinical pharmacists are involved in the entire treatment process from the beginning of patient hospitalization including medication reconciliation, participating in clinical ward rounds, providing medication consultation and so on. By monitoring DRPs and carrying out the appropriate interventions, clinical pharmacists play an increasingly important role in improving the efficacy and safety of medication therapy [10–14].

Studies from different countries discovered an average of 0.29–1.45 DRPs per patient admitted into the neurology unit [15–18]. These studies further indicate that clinical pharmacists can effectively identify and resolve DRPs in patients with neurological diseases. However, the prevalence and characteristics of DRPs in patients admitted into the neurology unit in China and factors associated with the occurrence of DRPs in this population are largely unknown.

Methods
Setting and study design
This retrospective study was performed in the 21-bed neurology unit on patients hospitalized from Apr 1, 2018 to Sep 31, 2020 at the Southern District of Beijing Tongren Hospital affiliated to Capital Medical University, a 1759-bed tertiary care, teaching and researching institution. Patients admitted into the neurology unit were cared for by a MDT, including a clinical pharmacist. The clinical pharmacist had obtained clinical pharmacy training certificates from the China Ministry of Health and had 5 years of hospital practice experience.

Data collection
Patients who required at least one overnight stay in the neurology unit were recruited during the study period. This period from Jan 1, 2020 to Jun 30, 2020 was not included in the study considering the effect of the novel coronavirus disease 2019 (COVID-19) on hospitalization rates. The clinical activities of the clinical pharmacist were: (1) reviewing medication orders to identify DRPs and proposing clinical interventions to resolve the DRPs identified; (2) visited the patients within 24-72 h of patient admission to the ward and medication reconciliation; (3) participating in daily MDT ward round and providing therapy advice to the MDT; (4) detecting and reporting adverse drug reactions; (5) providing discharge education. All DRPs identified by clinical pharmacists were documented, categorized, and entered into a data collection sheet. The sheet included patient clinical characteristics, types and causes of DRPs, pharmacists’ interventions, outcomes of interventions, and screenshots of DRPs. The following patient demographics and clinical information were collected: gender, age, smoking and drinking habits, body mass index (BMI), length of hospital stay, patient admission diagnosis, concomitant diseases, creatinine clearance, types of medications used, nasogastric feeding, number of medications used.

The identified DRPs, causes, interventions, and outcomes were categorized and characterized using the Pharmaceutical Care Network Europe (PCNE) DRP classification (version 9.00) system, which was last updated in 2019 [4]. The PCNE DRP classification system is a validated DRP classification used in a variety of settings, and it includes five domains: problems (P), causes (C), planned interventions (I), intervention acceptance (A), and status of the DRP (O). Although one problem may have multiple causes and lead to more than one intervention, it leads to only one outcome. The severity ratings of the outcomes of DRPs were categorized using the National Coordinating Council for Medication Error Reporting and Prevention (NCC-MERP) classification [19]. This classification comprises four categories according to ascending severity of the patient outcome: (1) circumstances or events that have the capacity to cause error (no error, subcategory A); (2) MEs occurred without posing harm to patients (subcategories B, C and D); (3) MEs caused harm to patients (subcategories E, F, G and H); (4) MEs resulted in a patient’s death (subcategory I). The severity ratings of DRPs were performed by two pharmacists independently.

Statistical analysis
We divided the patients into DRP and non-DRP groups. A descriptive analysis was performed on the patient’s demographics, clinical characteristics, identified DRPs, causes of DRPs, and types and outcomes of interventions. The Student’s t-test for continuous variables was used to compare means between groups when continuous variables conformed to the homogeneity of variance and normal distribution. Otherwise, the Mann-Whitney U test was used, represented by medians and interquartile ranges (IQRs) (25-75th percentiles). Categorical variables were represented by frequencies and percentages, and between-group differences were analyzed using the Chi-square test and Fisher’s exact test if necessary. Variance inflation factor (VIF) values were calculated to measure the degree of multicollinearity among the variables that were significant in the univariate analysis (p < 0.1). A VIF of > 10 was considered indicative of
multicollinearity and excluded from the logistic regression analysis. Based on the univariate analysis and VIF values, variables that were significant ($p < 0.1$) were included in the multiple logistic regression analysis to identify factors associated with the occurrence of DRPs. All statistical analyses were carried out using SPSS (Version 27.0). $p$ values $< 0.05$ were considered statistically significant.

**Results**

**Patient characteristics**

During the 24-month study period, 1225 patients were admitted to the neurology unit, 251 patients of them were excluded including 154 patients with less than one night, 95 patients admitting from Jan 2020 to Jun 2020, and 2 patients with no medication therapy. A total of 974 patients were eligible, and 198 (20.3%) patients had at least one DRP requiring pharmacist interventions. The median age of the study patients was 62.0(54.0,70.0) years and 65.9% were males. According to the International Classification of Diseases 10 (ICD-10), admitted patients suffered mainly from cerebrovascular disease, disorders of the optic nerve and visual pathways, episodic and paroxysmal disorders. The most common comorbidities were hyperlipidemia (82.9%), hypertension (70.2%), diabetes (35.8%), gastrointestinal diseases (28.6%), hyperhomocysteinemia (15.8%). Tables 1 and 2 provide the baseline characteristics of all patients and DRP status.

**Identified drug-related problems**

A total of 242 DRPs were identified, an average of 0.25 per patient (Table 3). Treatment Safety P2 was the major type of DRPs (106; 43.8%) followed by treatment effectiveness P1 (78;32.2%). Within the treatment effectiveness P1 category, the effect of drug treatment not optimal P1.2 was the dominant category. Unnecessary drug treatment P3.2 was the major category of Others P3.

**Causes of drug-related problems identified**

A total of 281 DRPs causes were identified (Table 4). Drug selection C1 was the primary cause of DRPs (124; 44.1%) followed by dose selection C3 (92;32.7%). Within the dose selection C3, dosage regimen too frequent C3.4 was the dominant subcategory followed by drug dose too high C3.2. Inappropriate drug according to guidelines/formulary C1.1 was the major subcategory in the drug selection domain C1.

**Pharmacists’ interventions to solve the drug-related problems**

A total of 525 interventions were suggested; an average of 2.2 interventions per DRP identified (Table 3). Most interventions occurred at the prescriber level I1 (241; 45.9%) followed by at the drug level I3 (238;45.3%). At the prescriber level, intervention proposed to prescriber I1.3 was the major subcategory; and instructions for use changed to ... I3.4 was the major subcategory at the drug level, followed by at the drug paused or stopped I3.5. Total 480 (91.4%) interventions were accepted and fully implemented by prescribers or patients, while 45 (8.6%) interventions were not accepted by prescribing physicians. 225 (93.0%) DRPs were totally solved, and 17 (7.0%) DRPs were unresolved (Table 3). Among the not solved O3 domain, lack of cooperation of prescriber O3.2 were the major causes of failed intervention outcome.

**Severity ratings of DRPs**

The severity ratings of DRPs from low to high were category B (107;44.2%), category C (79;32.6%), category D (24;9.9%), category E (25;10.3%) and category F (7;2.9%). A total of 86.8% of the DRPs were rated at severity categories B to D (causing no patient harm). None of DRPs was implicated to cause death (subcategory I). Medications that caused harm mainly included antihypertensive agents, insulin, diuretics, anti-infective drugs, and non-steroidal anti-inflammatory drugs. All-cause mortality in DRP and non-DRP groups were 0.

**Analysis of factors associated with the occurrence of DRPs**

Patients with DRPs had a higher median age in comparison with those without DRPs ($p < 0.005)$. The median length of hospital stay was 14.0 (11.0,15.0) days, and patients with DRPs had a longer duration of hospital stay, but no statistically significant difference ($p = 0.063$) (Table 1).

More DRPs were identified in patients with cerebrovascular disease, hypertension, diabetes, infectious diseases, and atrial fibrillation. Patients with DRPs also exhibited a lower median creatinine clearance than patients without DRPs ($p < 0.05$) (Table 1). The top 5 medication classes were antihyperlipidemic agents (86.4%), Traditional Chinese Medicine (85.2%), antiplatelet agents (81.9%), antihypertensive agents (71.0%) and digestive system medications (46.2%). Patients with DRPs exhibited greater use of antihypertensive agents, antidiabetic agents, anti-infective medications, anticoagulants, electrolytes, respiratory medications, and liver protective medications than patients without DRPs (Table 2). More patients with DRPs were placed on nasogastric feeding than patients without DRPs ($p < 0.001$). Of these nasogastric feeding in patients with DRPs, 13 DRPs involved inappropriate drug forms mainly included enteric coated, sustained, and controlled release dosage forms such as aspirin enteric-coated tablet, nifedipine controlled-release tablet. Patients with DRPs took a greater number of medications than...
Table 1 Patient demographic and disease characteristics

| Characteristics                                      | Total 974 (100%) | With DRP 198 (20.3%) | Without DRP 776 (79.7%) |
|-----------------------------------------------------|------------------|----------------------|------------------------|
| **Number**                                          |                  |                      |                        |
| **With DRP**                                        |                  |                      |                        |
| **Without DRP**                                     |                  |                      |                        |
| **Characteristics**                                 |                  |                      |                        |
| Sex, male                                           | 642 (65.9)       | 134 (67.7)           | 508 (65.5)             |
| Age                                                 | 62.0 (54.0,70.0) | 64.0 (55.0,73.0)     | 62.0 (53.0,69.0) **    |
| Smoke, currently                                    | 353 (36.2)       | 82 (41.4)            | 271 (34.9)             |
| Alcohol, currently                                  | 297 (30.5)       | 58 (29.3)            | 239 (30.8)             |
| Body mass index (kg/m2)                             | 25.2 (23.1,27.5) | 25.4 (23.5,26.9)     | 25.2 (23.0,27.6)       |
| Length of hospital stay, days                       | 14.0 (11.0,15.0) | 14.0 (11.0,15.0)     | 13.0 (11.0,15.0)       |
| Admission diagnosis                                 |                  |                      |                        |
| Cerebrovascular diseases a                          | 704 (72.3)       | 156 (78.8)           | 548 (70.6) *           |
| Episodic and paroxysmal disorders b                 | 64 (6.6)         | 11 (5.6)             | 53 (6.8)               |
| Disorders of the optic nerve and visual pathways c  | 65 (6.7)         | 8 (4.0)              | 57 (7.3)               |
| Demyelinating diseases of the central nervous system d | 21 (2.2)         | 4 (2.0)              | 17 (2.2)               |
| Paralytic strabismus o                             | 22 (2.3)         | 3 (1.5)              | 19 (2.4)               |
| Nerve, nerve root, and plexus disorders f           | 10 (1.0)         | 3 (1.5)              | 7 (0.9)                |
| Parkinson disease                                  | 5 (0.5)          | 2 (1.0)              | 3 (0.4)                |
| Myasthenia gravis                                  | 21 (2.2)         | 1 (0.5)              | 20 (2.6)               |
| Inflammatory diseases of the central nervous system g | 10 (1.0)         | 2 (1.0)              | 8 (1.0)                |
| Polyneuropathies and other disorders of the peripheral nervous system h | 7 (0.7) | 1 (0.5) | 6 (0.8) |
| Others                                             | 32 (3.3)         | 7 (3.5)              | 25 (3.2)               |
| Concomitant diseases                                |                  |                      |                        |
| Hyperlipidemia                                      | 807 (82.9)       | 168 (84.8)           | 639 (82.3)             |
| Hypertension                                        | 684 (70.2)       | 156 (78.8)           | 528 (68.0) **          |
| Diabetes                                            | 349 (35.8)       | 99 (50.0)            | 250 (32.2) ***         |
| Digestive system diseases                           | 279 (28.6)       | 67 (33.8)            | 212 (27.3)             |
| Hyperhomocysteinemia (HCY)                         | 154 (15.8)       | 38 (19.2)            | 116 (14.9)             |
| Liver dysfunction                                   | 128 (13.1)       | 34 (17.2)            | 94 (12.1)              |
| Coronary heart disease                             | 127 (13.0)       | 25 (12.6)            | 102 (13.1)             |
| Sleep disorder                                      | 107 (11.0)       | 26 (13.1)            | 81 (10.4)              |
| Creatinine clearance (ml/min)                       | 101.7 (80.3127.9)| 94.6 (74.91214)      | 103.3 (80.8129.1) *    |
| Respiratory diseases                                | 87 (8.9)         | 19 (9.6)             | 68 (8.8)               |
| Infectious diseases                                 | 74 (7.6)         | 36 (18.2)            | 38 (4.9) ***           |
| Hyperuricemia/gout                                  | 70 (7.2)         | 19 (9.6)             | 51 (6.6)               |
| Benign prostatic hyperplasia (BPH)                  | 70 (7.2)         | 17 (8.6)             | 53 (6.8)               |
| Peripheral neuropathy                               | 68 (7.0)         | 13 (6.6)             | 55 (7.1)               |
| Anxiety-depressive state                            | 41 (4.2)         | 10 (5.1)             | 31 (4.0)               |
| Deep venous thrombosis (DVT)                        | 37 (3.8)         | 12 (6.1)             | 25 (3.2)               |
| Atrial fibrillation                                 | 26 (2.7)         | 13 (6.6)             | 13 (1.7) ***           |

*p < 0.05; ** p < 0.005; ***p < 0.0001

*p Cerebral infarction, cerebral ischemia, cerebral haemorrhage; ** Transient ischemic attack, epilepsy, migraine; *** Anterior ischemic optic neuropathy, optic neuritis; d Multiple sclerosis, neuromyelitis optica spectrum disease; e Abducens nerve paralysis; f Diabetic mononeuropathy, trigeminal paralysis; g Purulent meningoencephalitis, nonspecific cavernous sinusitis; h Ischemic peripheral neuropathy, Guillain-Barre syndrome

patients without DRPs (13.5 (11.0,17.0) vs 11.0(9.0,14.0), p < 0.0001).

Before proceeding to multiple logistic regression analysis, 16 variables (p < 0.1) in the univariate analysis (including age, smoke, creatinine clearance, number of medications used, nasogastric feeding, diabetes, cerebrovascular diseases, hypertension and so on) were assessed for multicollinearity. The results showed that all VIF
values were less than 10, indicating the absence of multi-
collinearity. In multiple logistic regression analysis, fac-
tors of creatinine clearance, number of medications
used, nasogastric feeding, diabetes, infectious diseases as-
sociated with more frequent DRPs ($p < 0.05$) (Table 5).

Discussion

This is the first retrospective study conducted in
China to categorically evaluate DRPs using PCNE
classification, and to identify factors associated with
the occurrence of DRPs in the neurology unit of a
tertiary care and academic teaching hospital in China.
DRPs were relatively common in the neurology unit,
an average of 0.25 per patient. This number was close
to that in two studies, 0.39 from one study conducted
in the neurology ward in Switzerland by pharmacists
[18], and 0.29 from the other study done in the in-
patient ward and intensive care unit of the depart-
ment of neurology in Egypt [16]. However, the
average number of DRPs per patient in this study was
lower than the following two studies: (1) the Brazilian
study (1.26 DRPs per patient) using the trigger DRP
classification [15], (2) the Iran research (1.37 DRPs
per patient) using the modified PCNE DRP classifica-
tion V5.01 [17]. These studies showed a significantly
different mean number of DRPs per patient in
different hospitals. Study population size and setting,
characteristics of the patient population, study dur-
ation, definition of DRPs, types of classification sys-
tems, patterns of medication use, and differences of
clinical guidelines may contribute to the variations of
DRPs prevalence among studies [20–22].

Multiple logistic regression showed that creatinine
clearance, number of medications used, nasogastric feeding, diabetes, and infectious diseases were factors associ-
ated with DRPs. The findings that age and length of
hospital stay were not factors predicting the occurrence
of DRPs in our analysis were different from previous
studies [15, 16, 23]. It was worth noting that whether pa-
tients were fed through nasogastric feeding was an im-
portant factor associated with DRPs. Since a significant
proportion of patients admitted to the neurology unit
may require nasogastric feeding, the use of modified-
release drug products such as nifedipine controlled-release tablets, felodipine sustained-release tablets, and aspirin enteric-coated tablets when crushed
may alter the release profile and location, which may
affect its effectiveness and safety. However, because the
doctors lacked knowledge on differences of various types
of dosage forms, patients that were fed through nasoga-
stric feeding were more likely to have DRPs [21].

Table 2 Baseline medication class in patients

| Medication                  | Total (%) | With DRP (%) | Without DRP (%) |
|-----------------------------|-----------|--------------|-----------------|
| Antiplatelet agents         | 798 (81.9)| 171 (86.4)   | 627 (80.8)      |
| Anticoagulants              | 44 (4.5)  | 18 (9.1)     | 26 (3.4) **     |
| Antihyperlipidemic agents   | 842 (86.4)| 177 (89.4)   | 665 (85.7)      |
| Antihypertensive agents     | 692 (71.0)| 165 (83.3)   | 527 (67.9) ***  |
| Antidiabetic agents         | 318 (32.6)| 90 (45.5)    | 228 (29.4) ***  |
| Glucocorticoids             | 96 (9.9)  | 17 (8.6)     | 79 (10.2)       |
| Antiepileptic medications   | 10 (1.0)  | 2 (1.0)      | 8 (1.0)         |
| vitamins                    | 258 (26.5)| 47 (23.7)    | 211 (27.2)      |
| Treatment of prostatic hyperplasia | 35 (3.6)  | 8 (4.0)      | 27 (3.5)        |
| Digestive system medications| 450 (46.2)| 103 (52.0)   | 347 (44.7)      |
| Electrolytes                | 192 (19.7)| 49 (24.7)    | 143 (18.4) *    |
| TCM medications             | 830 (85.2)| 173 (87.4)   | 657 (84.7)      |
| Respiratory medications     | 93 (9.5)  | 29 (14.6)    | 64 (8.2) *      |
| Antianxiety or Antidepressant| 39 (4.0)  | 10 (5.1)     | 29 (3.7)        |
| Sedative hypnotics          | 108 (11.1)| 26 (13.1)    | 82 (10.6)       |
| Anti-infective medications  | 93 (9.5)  | 37 (18.7)    | 56 (7.2) ***    |
| Liver protective medications| 113 (11.6)| 31 (15.7)    | 82 (10.6) *     |
| Others                      | 59 (6.1)  | 10 (5.1)     | 49 (6.3)        |

*p < 0.05; ** p < 0.005; *** p < 0.0001
Abbreviation: TCM traditional Chinese medicine
In our study, treatment safety was the major type of DRPs. The result was different compared to the Brazilian and Egypt study, where the untreated condition was the major type of DRP identified. The result indicates the unique role that clinical pharmacists in China play in ensuring the safe use of medications for patients.
neurology unit. Drug selection and dose selection accounted for approximately 80% of the causes of the DRPs in our study. Inappropriate drugs according to guidelines/formulary was the major subcategory in the drug selection domain. For example, ischemic stroke patients took clopidogrel bisulfate tablets in combination with omeprazole sodium enteric-coated tablets leading to a decrease in the efficacy of clopidogrel. Hypertensive patients with hyperuricemia were treated with hydrochlorothiazide. This demonstrates that clinical pharmacists play an influential role in optimizing medication therapy in the MDT. Within the dose selection, dosage regimen too frequent was the dominant subcategory followed by drug dose too high. Many medications require dose adjustments for patients with old age and kidney or liver function impairment. This indicates the importance of clinical pharmacists to conduct prospective prescription reviews to ensure correct dosage and frequency of medication.

In our study, 525 interventions were suggested by the clinical pharmacist with a mean of 2.2 interventions per DRP, and interventions were highly accepted (91.4%). Previous studies showed a significantly different acceptance rate varying from 41.91 to 90.9% [15–18, 25]. The highest rate of acceptance so far demonstrates that pharmacist interventions were highly useful for physicians and a sufficient relationship of trust between physicians and pharmacists. The fact that 86.8% of DRPs were rated at severity categories B to D (causing no patient harm) further proves the importance of clinical

| Primary domain | Cause of the problem | Total number = 281 (100.0%) |
|----------------|----------------------|-----------------------------|
| Drug selection C1 | Inappropriate drug according to guidelines/formulary C1.1 | 33 (11.7) |
| | Inappropriate drug (within guidelines but otherwise contraindicated) C1.2 | 16 (5.7) |
| | No indication for drug C1.3 | 7 (2.5) |
| | Inappropriate combination of drugs, or drugs and herbal medications, or drugs and dietary supplements C1.4 | 15 (5.3) |
| | Inappropriate duplication of therapeutic group or active ingredient C1.5 | 14 (5.0) |
| | No or incomplete drug treatment in spite of existing indication C1.6 | 25 (8.9) |
| | Too many drugs prescribed for indication C1.7 | 14 (5.0) |
| Drug form C2 | Inappropriate drug form (for this patient) C2.1 | 13 (4.6) |
| Dose selection C3 | Drug dose too low C3.1 | 8 (2.8) |
| | Drug dose too high C3.2 | 33 (11.7) |
| | Dosage regimen not frequent enough C3.3 | 7 (2.5) |
| | Dosage regimen too frequent C3.4 | 37 (13.2) |
| | Dose timing instructions wrong, unclear or missing C3.5 | 25 (8.9) |
| Treatment duration C4 | Duration of treatment too short C4.1 | 1 (0.4) |
| | Duration of treatment too long C4.2 | 1 (0.4) |
| Drug use process C6 | Inappropriate timing of administration and/or dosing intervals C6.1 | 1 (0.4) |
| Patient related C7 | Patient uses/takes more drug than prescribed C7.2 | 1 (0.4) |
| | Inappropriate timing or dosing intervals C7.7 | 13 (4.6) |
| | Patient administers/uses the drug in a wrong way C7.8 | 1 (0.4) |
| | Patient unable to use drug/form as directed C7.9 | 1 (0.4) |
| Patient transfer related C8 | No medication reconciliation at patient transfer C8.1 | 2 (0.7) |
| | No updated medication list available C8.2 | 1 (0.4) |
| | Discharge/transfer information about medication incomplete or missing C8.3 | 2 (0.7) |
| | Patient has not received necessary medication at discharge from hospital or clinic C8.5 | 1 (0.4) |
| Other C9 | Other cause; specify C9.2 | 9 (3.2) |

Abbreviations: C cause
pharmacists in preventing medication errors and ensuring medication safety.

Our study has the following limitations: (1) this was a single-center study and patient populations admitted into the neurology unit could not include all neurologic diseases due to specializations of the department, so our findings may not be generalizable to other hospitals and neurology units in China, and (2) medication review was performed by one clinical pharmacist, and (3) our study did not assess the relationship between patients’ long-term outcomes and the resolution of DRPs.

**Conclusion**

This study indicates that the prevalence of DRPs is relatively common in Chinese neurology patients. Treatment safety is the major type of DRPs. Improving clinical pharmacy services in neurology unit could contribute to rational medication use and ensure patient safety.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

Study concept and design (Pengpeng Liu, Guangyao Li), Acquisition, analysis and interpretation of data (Pengpeng Liu, Guangyao Li, Mei Han), and drafting the manuscript and the final approval of the version to be published (Pengpeng Liu, Guangyao Li, Mei Han, Chao Zhang). All authors read and approved the final manuscript.

**Funding**

None.

**Table 5** Multiple logistic regression analysis of factors associated with the occurrence of DRPs

| Factors                        | Adjusted OR (95% CI) | p value |
|--------------------------------|----------------------|---------|
| Age                            | 1.000 (0.982–1.019)  | 0.997   |
| Sex                            | 1.423 (0.892–2.270)  | 0.138   |
| Smoke, currently               | 1.098 (0.706–1.709)  | 0.678   |
| Creatinine clearance           | 0.993 (0.986–0.999)  | 0.030   |
| Number of medications used     | 1.082 (1.025–1.141)  | 0.004   |
| Nasogastric feeding            | 3.882 (1.033–14.587) | 0.045   |
| Diabetes                       | 1.835 (1.227–2.744)  | 0.003   |
| Cerebrovascular diseases       | 0.829 (0.520–1.320)  | 0.429   |
| Hypertension                   | 1.329 (0.834–2.120)  | 0.232   |
| Infectious diseases            | 3.772 (1.822–7.808)  | <0.001  |
| Atrial fibrillation            | 1.566 (0.452–5.424)  | 0.479   |
| Anticoagulants                 | 1.181 (0.454–3.070)  | 0.734   |
| Respiratory medications        | 0.502 (0.220–1.144)  | 0.101   |
| Length of hospital stay        | 0.972 (0.924–1.024)  | 0.286   |
| Liver dysfunction              | 1.321 (0.763–2.286)  | 0.320   |
| Electrolytes                   | 1.399 (0.849–2.305)  | 0.187   |

**Availability of data and materials**

The data used to support the findings of this study are included within the article. If further information is required, the authors will furnish the additional supporting data.

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the Beijing Tongren Hospital Ethics Committee (NO. TRECKY2020–161). Patients were exempt from informed consent.

**Consent for publication**

Not applicable.

**Competing interests**

All authors declare no conflict of interest.

**Author details**

1. Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, 1 Dongjiaominxiang Street, Dongcheng District, Beijing 100730, China. 2. Evidence-Based Medicine Center, Beijing University of Chinese Medicine, Beijing, China.

**Received:** 19 June 2021 **Accepted:** 5 October 2021

**Published online:** 26 October 2021

**References**

1. Liu P, Liu Y, Zhang Y, Shi Q, Kong Y, Wang M, et al. Identification and rational medication use and ensure patient safety.

**Table 5** Multiple logistic regression analysis of factors associated with the occurrence of DRPs

| Factors                        | Adjusted OR (95% CI) | p value |
|--------------------------------|----------------------|---------|
| Age                            | 1.000 (0.982–1.019)  | 0.997   |
| Sex                            | 1.423 (0.892–2.270)  | 0.138   |
| Smoke, currently               | 1.098 (0.706–1.709)  | 0.678   |
| Creatinine clearance           | 0.993 (0.986–0.999)  | 0.030   |
| Number of medications used     | 1.082 (1.025–1.141)  | 0.004   |
| Nasogastric feeding            | 3.882 (1.033–14.587) | 0.045   |
| Diabetes                       | 1.835 (1.227–2.744)  | 0.003   |
| Cerebrovascular diseases       | 0.829 (0.520–1.320)  | 0.429   |
| Hypertension                   | 1.329 (0.834–2.120)  | 0.232   |
| Infectious diseases            | 3.772 (1.822–7.808)  | <0.001  |
| Atrial fibrillation            | 1.566 (0.452–5.424)  | 0.479   |
| Anticoagulants                 | 1.181 (0.454–3.070)  | 0.734   |
| Respiratory medications        | 0.502 (0.220–1.144)  | 0.101   |
| Length of hospital stay        | 0.972 (0.924–1.024)  | 0.286   |
| Liver dysfunction              | 1.321 (0.763–2.286)  | 0.320   |
| Electrolytes                   | 1.399 (0.849–2.305)  | 0.187   |

Availability of data and materials

The data used to support the findings of this study are included within the article. If further information is required, the authors will furnish the additional supporting data.

Declarations

Ethics approval and consent to participate

This study was approved by the Beijing Tongren Hospital Ethics Committee (NO. TRECKY2020–161). Patients were exempt from informed consent.

Consent for publication

Not applicable.

Competing interests

All authors declare no conflict of interest.

Author details

1. Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, 1 Dongjiaominxiang Street, Dongcheng District, Beijing 100730, China. 2. Evidence-Based Medicine Center, Beijing University of Chinese Medicine, Beijing, China.

Received: 19 June 2021 Accepted: 5 October 2021

Published online: 26 October 2021

References

1. Liu P, Liu Y, Zhang Y, Shi Q, Kong Y, Wang M, et al. Identification and rational medication use and ensure patient safety.

**Table 5** Multiple logistic regression analysis of factors associated with the occurrence of DRPs

| Factors                        | Adjusted OR (95% CI) | p value |
|--------------------------------|----------------------|---------|
| Age                            | 1.000 (0.982–1.019)  | 0.997   |
| Sex                            | 1.423 (0.892–2.270)  | 0.138   |
| Smoke, currently               | 1.098 (0.706–1.709)  | 0.678   |
| Creatinine clearance           | 0.993 (0.986–0.999)  | 0.030   |
| Number of medications used     | 1.082 (1.025–1.141)  | 0.004   |
| Nasogastric feeding            | 3.882 (1.033–14.587) | 0.045   |
| Diabetes                       | 1.835 (1.227–2.744)  | 0.003   |
| Cerebrovascular diseases       | 0.829 (0.520–1.320)  | 0.429   |
| Hypertension                   | 1.329 (0.834–2.120)  | 0.232   |
| Infectious diseases            | 3.772 (1.822–7.808)  | <0.001  |
| Atrial fibrillation            | 1.566 (0.452–5.424)  | 0.479   |
| Anticoagulants                 | 1.181 (0.454–3.070)  | 0.734   |
| Respiratory medications        | 0.502 (0.220–1.144)  | 0.101   |
| Length of hospital stay        | 0.972 (0.924–1.024)  | 0.286   |
| Liver dysfunction              | 1.321 (0.763–2.286)  | 0.320   |
| Electrolytes                   | 1.399 (0.849–2.305)  | 0.187   |
14. Lenssen R, Heidenreich A, Schulz JB, Trautwein C, Fitzner C, Jaehe U, et al. Analysis of drug-related problems in three departments of a German University hospital. Int J Clin Pharm. 2016;38(1):119–26. https://doi.org/10.1007/s11096-015-0213-1.

15. Rodrigues JPV, Marques FA, Gonçalves AMRF, Campos MSA, Reis TM, Morelo MRS, et al. Analysis of clinical pharmacist interventions in the neurology unit of a Brazilian tertiary teaching hospital. PLoS One. 2019;14(1):e0210779. https://doi.org/10.1371/journal.pone.0210779.

16. Ali MAS, Khedr EMH, Ahmed FAH, Mohamed NNE. Clinical pharmacist interventions in managing drug-related problems in hospitalized patients with neurological diseases. Int J Clin Pharm. 2018;40(5):1257–64. https://doi.org/10.1007/s11096-018-0658-0.

17. Foroughinia F, Tazarehie SR, Petramfar P. Detecting and managing drug-related problems in the neurology ward of a tertiary care teaching hospital in Iran: a clinical pharmacist’s intervention. J Res Pharm Pract. 2016;5(4):285–9. https://doi.org/10.4103/2279-042X.192455.

18. Taegtmeyer AB, Curkovic I, Corti N, Rosen C, Egbring M, Russmann S, et al. Drug-related problems and factors influencing acceptance of clinical pharmacists’ alerts in a large cohort of neurology inpatients. Swiss Med Wkly. 2012;142:w13615. https://doi.org/10.4414/smw.2012.13615.

19. The National Coordinating Council for Medication Error Reporting and Prevention Index. http://www.nccmerp.org/types-medication-errors. Accessed 12 May 2021.

20. Qu C, Meng L, Wang N, Chen Y, Yang X, Wang J, et al. Identify and categorize drug-related problems in hospitalized surgical patients in China. Int J Clin Pharm. 2019;41(1):13–7. https://doi.org/10.1007/s11096-018-0777-7.

21. Semcharoen K, Supompun S, Nathsuwan S, Kongwattrachapong J. Characteristic of drug-related problems and pharmacists’ interventions in a stroke unit in Thailand. Int J Clin Pharm. 2019;41(4):880–7. https://doi.org/10.1007/s11096-019-00852-4.

22. Chen Q, Jin Z, Zhang P, Sun S, Li L, Liao Y. Characteristics of drug-related problems among hospitalized ischemic stroke patients in China. Int J Clin Pharm. 2020;42(4):1237–41. https://doi.org/10.1007/s11096-020-01081-6.

23. Suggett E, Marriott J. Risk factors associated with the requirement for pharmaceutical intervention in the hospital setting: a systematic review of the literature. Drugs Real World Outcomes. 2016;3(3):241–63. https://doi.org/10.1007/s40801-016-0083-4.

24. Stavroulakis T, McDermott CJ. Enteral feeding in neurological disorders. Pract Neurol. 2016;16(5):352–61. https://doi.org/10.1113/practneurol-2016-004108.

25. Hu YZ, Cao ML, Xu DH, Wang J, Lu X. Clinical pharmacist interventions on a Chinese neurology ward: a 2-year service evaluation. Int J Clin Pharmacol Ther. 2016;54(8):581–6. https://doi.org/10.5414/CP202462.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.